Reconstitution of interleukin-17-producing T helper cells after allogeneic hematopoietic cell transplantation

Biol Blood Marrow Transplant. 2013 Mar;19(3):357-65. doi: 10.1016/j.bbmt.2012.11.018. Epub 2012 Nov 30.

Abstract

Interleukin 17A (IL-17)-producing CD4(+) T helper type 17 (Th17) cells have recently drawn attention as possible effector cells of acute graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) in murine models. Their role after allogeneic HCT in humans is unknown. In this prospective study, Th17, Th1/17, and Th1 cells were quantified in the peripheral blood of 80 patients within the first 3 months after allogeneic HCT using intracellular cytokine staining and flow cytometry. Within the observation period, Th1, Th1/17, and Th17 cells did not reconstitute to levels of healthy control subjects. In contrast to Th1 cells, no further expansion of Th1/17 and Th17 cells was observed during the first month after HCT. Antithymocyte globulin during conditioning significantly reduced the frequency of Th1/17 and Th17 cells but not of Th1 cells. Acute GVHD was not associated with significant changes in the size of the Th1, Th1/17, or Th17 cell subsets. Cytomegalovirus reactivation triggered the expansion of all T helper subsets, and Th1 cells showed the strongest increase. In contrast, no significant changes were found in the T helper cell compartment of patients with bacterial infections compared with time-matched control subjects. In conclusion, quantitative reconstitution of Th1, Th1/17, and Th17 cells is impaired within the first 3 months after HCT, especially when antithymocyte globulin is administered during conditioning. Cytomegalovirus reactivation, but not acute GVHD or bacterial infection, triggered the absolute expansion of these T cell subsets.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antilymphocyte Serum / pharmacology
  • Antilymphocyte Serum / therapeutic use
  • Bacterial Infections / immunology
  • Bacterial Infections / pathology
  • Cell Proliferation / drug effects
  • Cytomegalovirus Infections / immunology
  • Cytomegalovirus Infections / pathology*
  • Female
  • Graft vs Host Disease / prevention & control
  • Hematologic Diseases / immunology
  • Hematologic Diseases / pathology*
  • Hematologic Diseases / therapy
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Interleukin-17 / biosynthesis
  • Interleukin-17 / immunology*
  • Male
  • Middle Aged
  • Myeloablative Agonists / pharmacology
  • Myeloablative Agonists / therapeutic use
  • Th1 Cells / drug effects
  • Th1 Cells / immunology
  • Th1 Cells / pathology*
  • Th17 Cells / drug effects
  • Th17 Cells / immunology
  • Th17 Cells / pathology*
  • Transplantation Conditioning*
  • Transplantation, Homologous

Substances

  • Antilymphocyte Serum
  • IL17A protein, human
  • Interleukin-17
  • Myeloablative Agonists